Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics is well positioned by ZORYVE’s accelerating commercial momentum, with 2Q26 sales of $129.9 million rising 23% sequentially and 59% year over year, while total 2026 sales guidance was raised to $525 million-$540 million. The outlook is further supported by expanding access and distribution initiatives, including a dermatology sales force increase from 130 to 160 reps, a new PCP/pediatric effort, a June virtual health platform, and a July AI-enabled prescription workflow partnership that should broaden patient reach and streamline fulfillment. Fundamentally, the company is also benefiting from profitability and cash generation, reporting 2Q26 net income of $15.0 million, about $239 million in cash, and continued positive cash flow, while additional studies in adult itch, nail psoriasis, and PD1/PDL1-related dermatoses expand the franchise opportunity.

Arcutis Biotherapeutics is viewed negatively because ZORYVE must win against generic topical products and recently approved Vtama, while uptake depends on physician demand and payor access under intensive prior authorization, creating a high-friction commercialization path. The company also depends on Interquim for ZORYVE supply and manufacturing, adding third-party execution risk that could disrupt availability or delay growth. Financially, 1Q26 showed an $11.3MM net loss, and despite ~$224MM in cash, rising operating expenses in commercialization and pipeline development imply a continuing need for additional capital and leave downside risk from slower uptake, weaker GTN, and manufacturing issues.